Suzhou Connect Biopharmaceuticals, Ltd.
HomeحContact UsحSite Map
NEWS
Connect Biopharma CEO Dr. Zheng Wei Selected to National Thousand Talents Plan
(Taicang, Jiangsu, China, May 9, 2015)
Suzhou Connect Biopharmaceuticals, Ltd. announced today that the companys co-founder and CEO Dr. Zheng Wei has been selected to receive the National Distinguished Expert recognition from the Thousand Talents Plan. The title is given to entrepreneurial talents with experiences in starting a business overseas or serving as middle or senior-level managers in renowned international enterprises for more than 3 years and are founders of their business in China. Awardees are selected on the basis of their past achievements, the competitiveness and potential of commercialization of the novel technologies in their new businesses.
 
We are extremely pleased to learn that Dr. Zheng Wei has been selected to receive the award, said Dr. William (Wubin) Pan, cofounder and Chairman of Connect. "'The Thousand Talents Plan' is the highest recognition for returning entrepreneurial talents. The selection of Dr. Zheng Wei for this award is not only a testimony of his international experiences and achievements in technology innovations in drug discovery, but also a strong recognition of Connect's business strategies and rapid progress in building an immune modulator product pipeline since he cofounded the company three years ago.
 
About Suzhou Connect Biopharmaceuticals, Ltd.
Suzhou Connect biopharma is a clinical-stage company that discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. We identify and advance our drug candidates through in-house discovery and in-licensing, while leveraging qualified CROs for further development. We are currently evaluating, in a Phase I clinical trial, our lead drug candidate CBP-307, a second generation S1P1 (a G-protein coupled receptor -GPCR) modulator with best-in-class potential for the treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease and psoriasis. Meanwhile, we are advancing other preclinical programs including CBP-174 and CBP-201. CBP-174 is a small molecule inhibitor of a GPCR involved in allergic rhinitis and atopic dermatitis. This is an in-licensed program in which we hold exclusive global development and commercialization rights. CBP-201 is an internally-discovered monoclonal antibody for the treatment of asthma, atopic dermatitis and other diseases.
 
Media Contact:
Rosemary Chang
0512-53577866
 
For "The 1000 Talents Plan" award announcement, please refer to http://www.1000plan.org/qrjh/article/61669
 
 

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.